Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

ANG Lifesciences India Ltd - 540694 - Standalone & Consolidated Un-Audited Financial Results Of The Company For The Quarter And Nine Month Ended December 31, 2022 Along With The Limited Review Report

 Pursuant to Regulation 30 & 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors in its meeting held on Tuesday, 14th February, 2023 has considered and approved the Standalone & Consolidated Un-Audited Financial Results of the Company for the Quarter and Nine month ended December 31, 2022 along with the Limited Review Report thereon issued by M/s Raman Wadhwa & Co., Statutory Auditors of the Company.
14-02-2023
Bigul

ANG Lifesciences India Ltd - 540694 - Board Meeting Outcome for Outcome Of Board Meeting Pursuant To Reg. 30 Of SEBI (Listing Obligation And Disclosure Requirements), Regulation, 2015.

 Pursuant to Regulation 30 & 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors in its meeting held on Tuesday, 14th February, 2023 has considered and approved the Standalone & Consolidated Un-Audited Financial Results of the Company for the Quarter and Nine month ended December 31, 2022 along with the Limited Review Report thereon issued by M/s Raman Wadhwa & Co., Statutory Auditors of the Company.
14-02-2023
Bigul

ANG Lifesciences India Ltd - 540694 - Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulation, 2015

 ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 ,inter alia, to consider and approve Pursuant to Regulation 29 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 ('LODR'), we hereby inform you that a Meeting of the Board of Directors of the Company is scheduled to be held on February 14th, 2023 at 04:30 PM at the Registered Office of the Company to consider and approve the Unaudited Standalone & Consolidated Financial Results along with Limited Review Report thereon for the Quarter and Nine Months ended 31st December, 2022 and transact any other matter, if any with permission of the Chair.
06-02-2023
Bigul

ANG Lifesciences India Ltd - 540694 - Announcement under Regulation 30 (LODR)-Meeting Updates

 Pursuant to Regulation 30 of SEBI (Listing Obligation & Disclosure Requirements), 2015, it is hereby informed that the business purchase agreement executed between ANG Lifesciences India Limited and ANG Healthcare India Pvt Ltd has not been accomplished. According to terms and condition, M/s ANG Healthcare did not fulfilled the growth parameters within the stipulated time period. Therefore consequent to the lack of due diligence, the Company's board of director in their meeting held on today i.e. 30th January, 2023, decided to call-off/ terminate the agreement of acquisition of ANG Healthcare India Pvt Ltd. Further the necessary formalities or compliance in this respect will be initiated and completed in due course of time.
30-01-2023
Bigul

ANG Lifesciences India Ltd - 540694 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 We are enclosing herewith Certificate dated January 25, 2023 issued by Bigshare Services Private Limited, Registrar and Transfer Agent (RTA) of the Company for the quarter ended 31-Dec-2022 confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
25-01-2023
Bigul

ANG Lifesciences India Ltd - 540694 - Closure of Trading Window

 Dear Sir/ Ma'am, Pursuant to SEBI (Prohibition of Insider Trading) Regulation, 2015 as amended from time to time read with Company's code of conduct to regulate, monitor and report the trading of equity shares, the Trading window of the Company shall remain closed from 01-Jan-2023 for the insider, designated persons of the Company and their immediate relatives, till the end of 48 hours after the declaration of Unaudited Financial Result for the quarter and nine months ended as at 31-Dec-2022. The date of Board Meeting of the Company to consider and approve, inter alia, Unaudited Financial Results of the Company for the quarter and nine months ended as at 31-Dec-2022 shall be intimated separately.
30-12-2022
Bigul

ANG Lifesciences India Ltd - 540694 - Intimation Of Resignation Of Chief Financial Officer As Per Regulation 30 Of The SEBI (LODR) Regulation, 2015.

 With reference to the captioned subject and in compliance with Regulation 30 read with Part A of Schedule III of the SEBI (LODR) Regulations, 2015, this is to inform you that Mr. Subodh Sharma has tendered his resignation from the post of Chief Financial Officer (KMP) of the company w.e.f. 5th December, 2022. (Enclosed Resignation Letter).
05-12-2022
Bigul

ANG Lifesciences India Ltd - 540694 - Intimation Of Allotment Of Equity Shares On Preferential Basis Under The Provision Of SEBI (ICDR) Regulations, 2018.

 We wish to inform you that the Board of Directors has considered and approved the allotment of 1,00,000 equity shares at an issue price of Rs. 200/- per share (face value of Rs. 10/- plus premium of Rs. 190/-) on preferential basis on today i.e., 29th November, 2022.
29-11-2022
Bigul

ANG Lifesciences India Ltd - 540694 - Disclosure Of Related Party Transactions For The Half Year Ended 30Th September, 2022.

 Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith disclosure of related party transactions on a consolidated basis, for the half year ended 30th September, 2022.
25-11-2022
Bigul

ANG Lifesciences India Ltd - 540694 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Submission of Newspaper publication of the Unaudited Financial Results (Consolidated & Standalone) for the quarter & half year ended on 30.09.2022
17-11-2022
Next Page
Close

Let's Open Free Demat Account